GLP-1 drugs linked to 37-68% higher hair loss risk in diabetes patients

A new study published in The BMJ has found that GLP-1 receptor agonists—the same drugs prescribed to millions of people with type 2 diabetes and obesity—are linked to a substantially higher risk of hair loss. Researchers analyzing data from the University of Pennsylvania Health System discovered that patients taking these medications experienced hair shedding at rates 37 to 68 percent higher than those on alternative diabetes drugs, depending on which comparison drug was used.

The finding arrives as GLP-1 agonists like semaglutide and tirzepatide have become among the most widely prescribed medications in America. While anecdotal reports of hair loss have circulated in online patient communities for years, this is among the first systematic studies to quantify the risk and compare it directly to other diabetes treatments. The researchers stressed that while the absolute risk remains modest—roughly 6 to 7 cases per 1,000 patients per year—the relative increase is significant enough to warrant clinical attention.

To reach these conclusions, the team examined electronic health records for more than 39,000 patients with type 2 diabetes who started treatment between January 2019 and September 2024. They compared 12,004 GLP-1 users against 15,221 patients taking SGLT-2 inhibitors, another class of diabetes drug, and separately compared 11,964 GLP-1 users with 11,233 patients on DPP-4 inhibitors. The groups were broadly similar in their underlying health profiles, though GLP-1 users tended to be younger and heavier at baseline.

After accounting for age, sex, ethnicity, existing medical conditions, other medications, and body mass index, the association held firm. GLP-1 users showed a 37 percent elevated risk compared to SGLT-2 inhibitor users and a 68 percent higher risk compared to DPP-4 inhibitor users. Notably, the hair loss appeared to be the non-scarring variety, meaning hair follicles remained intact and regrowth remained possible—a distinction that matters for long-term outcomes.

The researchers offered plausible explanations for the mechanism. Rapid weight loss, which these drugs are known to trigger, is a well-established trigger for hair shedding. The same weight loss can also deplete iron and zinc stores, both essential for normal hair growth cycles. Hormonal shifts accompanying significant weight reduction may also play a role, though the authors acknowledged that more research is needed to pin down exactly how these drugs affect hair follicles.

The study does carry limitations worth noting. The researchers lacked detailed clinical information about the severity of hair loss, how long it lasted, or whether it reversed after patients stopped taking the medication—questions that matter enormously to someone experiencing it. They also could not entirely rule out that unmeasured factors influenced their findings. Yet they emphasized that the analysis was rigorous, based on high-quality data from a large, representative patient population, and that results remained consistent across multiple analytical approaches.

The authors framed their work as an effort to move beyond anecdote toward systematic evidence. They argue that clinicians should now be aware of this potential side effect when discussing treatment options with patients, particularly those for whom hair loss might influence whether they stay on the medication. For patients already experiencing unexplained shedding while on a GLP-1 drug, the findings offer validation that the symptom is real and documented—and potentially reversible.